Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.61 |
| ▸ | PLD2 | O14939 | 1/20 | 0.54 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.54 |
| ▸ | NHERF1 | O14745 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13941453 | 0.92 | EGFR (0.58) | EGFRPIK3CAPLD2PLD1NHERF1 | |
| SCHEMBL13941573 | 0.88 | EGFR (0.51) | EGFRPIK3CAPLD2PLD1NHERF1 | |
| SCHEMBL13941576 | 0.88 | NPC1 (0.61) | EGFRPIK3CAPLD2PLD1NHERF1 | |
| SCHEMBL13941451 | 0.87 | EGFR (0.56) | EGFRPIK3CAPLD2PLD1NHERF1 | |
| SCHEMBL16108828 | 0.87 | EGFR (0.56) | EGFRPIK3CAPLD2PLD1NHERF1 | |
| SCHEMBL13941381 | 0.87 | EGFR (0.52) | EGFRPIK3CAPLD2PLD1NHERF1 | |
| SCHEMBL13941572 | 0.85 | TP53 (0.59) | EGFRPIK3CANPC1RAB9ARXFP1 | |
| SCHEMBL13941532 | 0.85 | EGFR (0.50) | EGFRPIK3CAPLD2PLD1NHERF1 | |
| SCHEMBL13941533 | 0.84 | EGFR (0.49) | EGFRPIK3CAPLD2PLD1NHERF1 | |
| SCHEMBL13941634 | 0.83 | EGFR (0.56) | EGFRPIK3CAPLD2PLD1NHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765802-B2 | Kinase inhibitors, compositions thereof, and methods of use therewith | PROVID PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | CHEK2, ATM, CHEK1 | EGFR 1827/4885PIK3CA 821/4885PLD2 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.